PMS-RISEDRONATE 150 MG
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) : 150 MG · DIN 02424177 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-RISEDRONATE?
PMS-RISEDRONATE 150 MG contains RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02424177, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-May-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-RISEDRONATE used for?
pms - RISEDRONATE (risedronate sodium) is indicated for: • the treatment and prevention of osteoporosis in postmenopausal women • the treatment of osteoporosis in men, to improve bone mineral density Postmenopausal Osteoporosis: In the treatment of osteoporosis in postmenopausal women at risk of fracture, risedronate sodium prevents vertebral and nonvertebral osteoporosis - related (fragility) fractures and increase bone mineral density (BMD) at all measured skeletal sites of clinical importance for osteoporotic fractures, including spine, hip, and wrist. For the prevention of osteoporosis in postmenopausal women who are at risk of developing osteoporosis, risedronate sodium preserves or increases BMD at sites of clinical importance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02424177 |
|---|---|
| Brand name | PMS-RISEDRONATE |
| Generic / active ingredient | RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) : 150 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M05BA07 RISEDRONIC ACID |
| AHFS class | 92:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-May-2014 |
| Original market date | 2014-05-28 00:00:00 |
How is it stored and handled?
null
How is it supplied?
35 mg: HDPE bottles of 30 tablets and blister package of 4 tablets. 150 mg: HDPE bottles of 30 tablets and blister package of 1 tablet.
What can be used instead?
Other Canadian products sharing ATC code M05BA07 RISEDRONIC ACID. 20 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-RISEDRONATE DR | 35 MG | TABLET (DELAYED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02493268 |
| ACTONEL | 150 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02316838 |
| ACTONEL | 35 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02246896 |
| ACTONEL DR | 35 MG | TABLET (DELAYED-RELEASE) | ABBVIE CORPORATION | MARKETED | DIN 02370417 |
| APO-RISEDRONATE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02377721 |
| APO-RISEDRONATE | 35 MG | TABLET | APOTEX INC | MARKETED | DIN 02353687 |
| AURO-RISEDRONATE | 35 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02406306 |
| NB-RISEDRONATE | Strength | Tablet | NB PHARMA INC. 208 2700 Rue Jean-Perrin Québec Quebec Canada G2C 1S9 | MARKETED | DIN 02561859 |
| PMS-RISEDRONATE | 35 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02302209 |
| RISEDRONATE | 150 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02528460 |
Who else supplies RISEDRONIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RISEDRONIC ACID appears in 16 registered pack listings across 2 markets, published on 1 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.